Companies › Shanghai Virogin Biotech
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout May 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| VG2062 Recombinant oncolytic HSV-1 expressing human IL-12 and IL-15 | – | Phase 1 | Advanced Malignant Solid Tumor | May 2027 |
| VG2025 Recombinant human IL-12/IL-15 dual-regulated oncolytic HSV-1 | – | Phase 1 | Advanced Malignant Solid Tumor | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05477849 | VG2025 | Phase 1 | Advanced Malignant Solid Tumor | Oncology | Oct 2025 |
| NCT07262164 | VG2062 | Phase 1 | Advanced Malignant Solid Tumor | Oncology | May 2027 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.